In 2026, the British-Swedish biopharmaceutical company AstraZeneca will launch contract production of five innovative medicines at the Skopinpharm plant in the Ryazan region. This was reported to GxP News by the press service of AstraZeneca’s Russian division.
These are drugs for the treatment of lung cancer, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome. It is also planned to produce medicines for adults with systemic lupus erythematosus, a children’s drug for the treatment of inoperable plexiform neurofibromas, and a drug for enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency.
“Cooperation with Skopinpharm is AstraZeneca’s first experience of contract production in Russia. This stage is provided by the company’s business model and is aimed at increasing the availability of innovative therapies to Russian patients,” AstraZeneca told our publication.
Secondary packaging and manufacturing quality control of drugs will be carried out at production facilities in the Ryazan region. Appropriate amendments have been made to their registration certificates.
AstraZeneca and Skopinpharm signed their cooperation agreement this summer. The agreement provides for the phased launch of contract production of AstraZeneca drugs over the coming years. The company owns its own plant in the Kaluga Region, launched in 2015. To date, it produces ten drugs.
